ATXN2 and amyotrophic lateral sclerosis: Given that accumulations of TDP-43 are by far the most common pathology seen in patients with ALS, these studies indicate that an ataxin-2-targeting ASO, if effective, has the potential to be therapeutically beneficial to large cohorts of patients with ALS, including patients with sALS.